Download Files:
SLC13A5-IN-1
$125 – $600
Products Details
Product Description
– SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5[1].
Web ID
– HY-125990
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C19H19Cl3N2O3S
References
– [1]Joerg Kley, et al. Sulfonamides as inhibitors of the uptake of extracellular citrate. Patent WO2018104220A1
CAS Number
– 2227548-95-8
Molecular Weight
– 461.79
Compound Purity
– 99.79
SMILES
– O=C(C1CCN(S(=O)(C2=CC(Cl)=CC(Cl)=C2)=O)CC1)NCC3=CC=C(Cl)C=C3
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease; Cardiovascular Disease
Solubility
– DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Sodium Channel
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
